Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas.
This study reports the first use of gene array technology for the identification of a tumor-specific marker in lymphoid neoplasms. The differential gene expression of 31 hematopoietic cell lines, representing most major lymphoma subgroups of B- and T-cell origin, was assessed by hybridizing labeled complementary DNA to Atlas human expression arrays containing 588 genes. Genes known to be specific for B, T, or myelomonocytic lineages were appropriately identified in the arrays, validating the general utility of this approach. One gene, clusterin, not previously known to be expressed in lymphoid neoplasms, was specifically found in all 4 anaplastic large-cell lymphoma (ALCL) cell lines, but not in any of the 27 remaining tumor lines. Using a monoclonal antibody against clusterin, its differential expression was confirmed by Western blotting and immunohistochemistry. A total of 198 primary lymphomas (representing most major lymphoma subtypes), including 36 cases of systemic ALCL, were surveyed for clusterin expression by immunohistochemistry and Western blotting. All of the 36 ALCL cases marked for clusterin, with most cases showing moderate to strong staining in the majority of neoplastic cells. Clusterin expression was not related to expression of anaplastic lymphoma kinase-1. With 2 exceptions, none of the remaining 162 non-ALCL cases marked with the clusterin antibody, including Hodgkin disease and primary cutaneous ALCL. In reactive lymphoid tissues, only follicular dendritic cells and fibroblastic reticular cells exhibited staining. Clusterin is a highly conserved glycoprotein implicated in intercellular and cell matrix interactions, regulation of the complement system, lipid transport, stress responses, and apoptosis. Although its function in ALCL is unknown, the unique expression of clusterin within this category of lymphoma provides an additional marker for the diagnosis of ALCL. This study illustrates the enormous potential of gene array technologies for diagnostic marker discovery. (Blood. 2000;96:398-404)
Wellmann
A
A
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Thieblemont
C
C
Pittaluga
S
S
Sakai
A
A
Jaffe
E S
ES
Siebert
P
P
Raffeld
M
M
D014408:Biomarkers, Tumor; D015153:Blotting, Western; D051152:Clusterin; D018076:DNA, Complementary / Q000032:analysis*; D015870:Gene Expression; D006023:Glycoproteins / Q000235:genetics*; D006689:Hodgkin Disease / Q000235:genetics; D006801:Humans; D008223:Lymphoma / Q000235:genetics*; D016393:Lymphoma, B-Cell / Q000235:genetics; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics; D016399:Lymphoma, T-Cell / Q000235:genetics; D018832:Molecular Chaperones; D009693:Nucleic Acid Hybridization; D017422:Sequence Analysis, DNA; D014407:Tumor Cells, Cultured
D014408:Biomarkers, Tumor; C495242:CLU protein, human; D051152:Clusterin; D018076:DNA, Complementary; D006023:Glycoproteins; D018832:Molecular Chaperones